Active Biotech AB Interim report January – June 2021
Good progress in the projects towards important clinical events SECOND QUARTER IN BRIEF Active Biotech…
Month: August 2021
Ultimovacs Announces First Patient Enrolled in Phase II FOCUS Trial of UV1 in Head-and-Neck Cancer
Study will assess the benefit of combining UV1 with standard of care pembrolizumab Topline data…
Ultimovacs announces first patient enrolled in Phase II FOCUS trial of UV1 in head-and-neck cancer
Study will assess the benefit of combining UV1 with standard of care pembrolizumab Topline data…
iOnctura Strengthens Management With Appointment of Sean A. MacDonald as Chief Business Officer
GENEVA, Switzerland, Aug. 05, 2021 (GLOBE NEWSWIRE) — iOnctura SA, a clinical stage oncology company…
Verona Pharma Reports Second Quarter 2021 Financial Results and Provides Corporate Update
ENHANCE Phase 3 program on track to report top-line data in 2022 Up to $219…
Noema Pharma Initiates Phase 2a Allevia Study of PDE10A Inhibitor NOE-105 in Tourette Syndrome
First Noema clinical trial, with asset in-licensed from Roche with strong clinical safety package Noema…
Valneva Announces Positive Phase 3 Pivotal Results for its Single-Shot Chikungunya Vaccine Candidate
Pivotal study VLA1553-301 met its primary endpoint Vaccine candidate induced protective CHIKV neutralizing antibody titers…
Addex Reports 2021 Half Year and Second Quarter Financial Results and Provides Corporate Update
Strong cash and cash equivalents position at June 30, 2021 of CHF18.1M ($19.6M) Pivotal dipraglurant…
ObsEva Announces Second Quarter 2021 Financial Results and Business Update
–Linzagolix (Yselty®) for uterine fibroids: US New Drug Application filing planned in Q3:21; European marketing…
Imugene and Celularity Announce an Exclusive Strategic Partnership to Develop a Novel Oncolytic Virus – Allogeneic CAR T-Cell Immunotherapy Combination for the Treatment of Solid Tumors
Collaboration will initially explore the therapeutic potential of a combination of Imugene’s CF33-CD19 oncolytic virus…
First Patient Dosed in CUPID Study of Telix’s Targeted Alpha Therapy Candidate for Prostate Cancer
MELBOURNE, Australia, Aug. 04, 2021 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the…
T2 Biosystems to Participate in the Canaccord Genuity 41st Annual Growth Conference
LEXINGTON, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the…
Sky Century Investment, Inc. Announces Its Plans to Expand Its CBD Products Assortment
Las Vegas, NV, Aug. 04, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Sky Century Investment,…
Tarsus Pharmaceuticals, Inc. Reports Second Quarter 2021 Financial Results and Provides Business and Clinical Updates
Announced positive results of the Saturn-1 pivotal trial evaluating TP-03 for the treatment of Demodex…
Alpha Healthcare Acquisition Corp. Sets August 24, 2021, for Special Shareholder Meeting to Vote on Humacyte Business Combination
Special shareholder meeting to approve, among other items, the proposed business combination with Humacyte, Inc….
OpGen Announces the Cancellation of Adjourned Portion of Annual Meeting
ROCKVILLE, Md., Aug. 04, 2021 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the…
Paratek Pharmaceuticals Announces NUZYRA® (omadacycline) Has Been Added to the CDC Plague Guidelines for the Treatment, Pre-Exposure and Postexposure Prophylaxis of Plague
BOSTON, Aug. 04, 2021 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical…
vTv Therapeutics Announces 2021 Second Quarter Financial Results and Provides Corporate Update
HIGH POINT, N.C., Aug. 04, 2021 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (Nasdaq:VTVT) today reported…
Parrot, Verizon and Skyward bring first 4G LTE connected drone to the U.S. market
First of its kind connected drone, Parrot ANAFI Ai is powered by Verizon 4G LTE…
Ocilion Expands Relationship with Amdocs Media’s Vubiquity in Multi-Year Content-as-a-Service Engagement
German-language IPTV provider ocilion selects Vubiquity to power their premium content offering via Vubiquity’s Content…